Wall Street brokerages expect Shire PLC (NASDAQ:SHPG) to post earnings per share of $3.53 for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Shire PLC’s earnings, with the lowest EPS estimate coming in at $3.36 and the highest estimate coming in at $3.66. Shire PLC posted earnings per share of $3.38 in the same quarter last year, which would suggest a positive year over year growth rate of 4.4%. The company is scheduled to report its next quarterly earnings report before the market opens on Thursday, August 3rd.
According to Zacks, analysts expect that Shire PLC will report full year earnings of $14.89 per share for the current financial year, with EPS estimates ranging from $14.41 to $15.20. For the next year, analysts anticipate that the firm will report earnings of $16.65 per share, with EPS estimates ranging from $15.24 to $18.45. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Shire PLC.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $0.41. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The firm had revenue of $3.57 billion for the quarter. During the same quarter last year, the company earned $2.12 EPS. Shire PLC’s revenue for the quarter was up 109.0% on a year-over-year basis.
SHPG has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated a “buy” rating and set a $221.00 price target on shares of Shire PLC in a report on Tuesday, March 14th. Jefferies Group LLC set a $239.00 target price on Shire PLC and gave the company a “buy” rating in a research note on Saturday, March 18th. Goldman Sachs Group, Inc. (The) reiterated a “focus list” rating on shares of Shire PLC in a research note on Tuesday, March 21st. HSBC Holdings plc downgraded Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Finally, Sanford C. Bernstein downgraded Shire PLC from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $223.01.
A number of institutional investors have recently modified their holdings of the stock. Capital One National Association raised its position in shares of Shire PLC by 3.4% in the second quarter. Capital One National Association now owns 7,982 shares of the biopharmaceutical company’s stock worth $1,319,000 after buying an additional 261 shares during the last quarter. Independent Portfolio Consultants Inc. raised its position in shares of Shire PLC by 27.8% in the second quarter. Independent Portfolio Consultants Inc. now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 354 shares during the last quarter. Bedell Frazier Investment Counseling LLC raised its position in shares of Shire PLC by 15.2% in the first quarter. Bedell Frazier Investment Counseling LLC now owns 26,068 shares of the biopharmaceutical company’s stock worth $4,542,000 after buying an additional 3,430 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Shire PLC by 45.3% in the first quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 350 shares during the last quarter. Finally, New South Capital Management Inc. purchased a new position in shares of Shire PLC during the first quarter worth about $87,954,000. 20.93% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “$3.53 EPS Expected for Shire PLC (NASDAQ:SHPG) This Quarter” was posted by WKRB News and is the property of of WKRB News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.wkrb13.com/markets/2286319/3-53-eps-expected-for-shire-plc-nasdaqshpg-this-quarter.html.
Shire PLC (NASDAQ:SHPG) traded down 2.49% during midday trading on Monday, reaching $163.29. 1,812,321 shares of the company’s stock were exchanged. The company has a market cap of $48.64 billion, a PE ratio of 167.48 and a beta of 1.60. Shire PLC has a 52 week low of $161.09 and a 52 week high of $209.22.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286319/3-53-eps-expected-for-shire-plc-nasdaqshpg-this-quarter.html
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.